PLRX
Pliant Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing medicines to treat fibrosis—the scarring that makes organs like the lungs and liver stiff. Pliant's name plays on its mission: its therapies aim to make rigid, scarred tissue "pliant," or flexible again. Founded in 2015 by researchers from the University of California, San Francisco, the company targets integrins, proteins that drive the scarring process, with drug candidates for fibrotic and cancer conditions.
CUSIP: 729139105HealthcareUS1 holder
Total Value
$354.3K
Total Shares
281.2K
Net Share Change
0
Activity
No changes
Investor
Value
Shares
Weight
Change
